Literature DB >> 3815393

Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.

J L Clark, S H Berger, A Mittelman, F G Berger.   

Abstract

We have identified amplification of the thymidylate synthase gene in a colonic tumor that had developed resistance to 5-fluorouracil/leucovorin combination chemotherapy. The tumor had previously undergone a partial response to this combination but began to progress following a prolonged period of continuous therapy and relative disease stabilization. Since thymidylate synthase is a target enzyme for 5-fluorouracil, it is likely that the observed gene amplification is responsible for the resistance. Thus, gene amplification may be a relevant mechanism of acquired resistance to fluoropyrimidine chemotherapy in the clinic.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815393

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  9 in total

Review 1.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 2.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

3.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

Authors:  Tian-Li Wang; Luis A Diaz; Katharine Romans; Alberto Bardelli; Saurabh Saha; Gennaro Galizia; Michael Choti; Ross Donehower; Giovanni Parmigiani; Ie-Ming Shih; Christine Iacobuzio-Donahue; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

4.  Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene.

Authors:  Kumiko Kitajima; Susumu Kobayashi; Hiroaki Shiba; Tadashi Uwagawa; Yuichi Ishida; Keisuke Aiba; Makio Kawakami; Katsuhiko Yanaga
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 5.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

6.  Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.

Authors:  M P Findlay; D Cunningham; G Morgan; S Clinton; A Hardcastle; G W Aherne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.

Authors:  S J Freemantle; A L Jackman; L R Kelland; A H Calvert; J Lunec
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

8.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

Authors:  A L Jackman; L R Kelland; R Kimbell; M Brown; W Gibson; G W Aherne; A Hardcastle; F T Boyle
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

9.  Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Authors:  I K Dev; R E Dornsife; T M Hopper; J A Onori; C G Miller; L E Harrington; K M Dold; R J Mullin; J H Johnson; R M Crosby; A T Truesdale; A H Epperly; K W Hinkle; M Cheung; J A Stafford; D K Luttrell; R Kumar
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.